Although Amicus believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions there can be no assurance that its expectations will be realized. Actual results could differ materially from those projected in Amicus’ forward-looking statements due to numerous known and unknown risks and uncertainties including the risk factors described in our annual report on Form 10(k) for the year ended December 31, 2011. All forward-looking statements are qualified in their entirety by this cautionary statement and Amicus undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date hereof.
At this time it is my pleasure to turn the call over to John Crowley, Chairman and Chief Executive Officer of Amicus.
Great, thank you Sara, and good evening everybody and thanks for joining. This is very, very good news that we’re happy to announce this evening. As Sara indicated I’m joined by a number of members of the Executive Team here at Amicus, and before I turn it over to Brad and David in particular to take us through a number of different slides that hopefully everybody has now available to them – and we’ll reference those throughout this presentation – let me just reiterate why this is such a significant deal for Amicus and for continued collaboration and strengthening of that collaboration with GSK.Again, three major components to this transaction: first is the agreement that we will jointly develop with our partners at GSK a next generation proprietary enzyme replacement therapy in Fabry disease that co-formulates and utilizes our core platform technology – the use of the chaperone migalastat; so a proprietary ERT developed by GSK, and we’ll talk more about the history of that development here and how it came to be and the significance of that ERT now combined. So a propriety co-formulated ERT that’s been in development for some time.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV